# Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT04671251** · PHASE1 · COMPLETED · sponsor: **Avalo Therapeutics, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** AEVI-007

## Key facts

- **NCT ID:** NCT04671251
- **Lead sponsor:** Avalo Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-15
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04671251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04671251, "Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04671251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*